Urogenital multiplex polymerase chain reaction (PCR) panels report Mycoplasma genitalium (MG) and Mycoplasma hominis (MH) similarly despite different clinical significance. We retrospectively analyzed 176,855 adult specimen-level laboratory records (2018–2022). MG and MH were compared using modified Poisson regression and a year-adjusted stacked interaction model. MG was detected in 4215 records (2.38%) and MH in 8024 (4.54%). MG prevalence fell from 4.48% (95% confidence interval (CI), 4.30–4.68) at 18–29 years to 0.21% (0.16–0.27) at ≥60 years, whereas MH fell from 5.70% to 2.39%. Female sex was associated with lower MG (adjusted prevalence ratio [aPR], 0.32) and higher MH (1.44). Age and sex gradients differed significantly (interaction PRs, 1.519 and 4.653; both p < 0.001), whereas no specimen-type interaction reached significance (all p ≥ 0.19). No other target was positive in 52.1% of MG-positive versus 54.5% of MG-negative records, but in 4.9% of MH-positive versus 55.7% of MH-negative records. MH co-detection was strongest with Gardnerella vaginalis (aPR, 9.94), Ureaplasma urealyticum (6.12), and Trichomonas vaginalis (5.48). These profiles support target-specific reporting. Cross-panel analytical differences cannot be excluded because MG and MH were measured on different panels.

This study aimed to determine the effect of an intervention for sarcopenia prevention using urban forest resources on sarcopenia, depression, and quality of life in community-dwelling older adult women aged ≥65 years. Older adult women (n = 59) were randomly assigned to the experimental group (n = 30), who participated in a forest-based intervention for sarcopenia prevention for older adults conducted twice a week for 8 weeks (16 sessions in total) and the control group (n = 29), who maintained their daily routine. We examined the sarcopenia indicators and psychological changes between the groups according to the participation duration and found significant changes in the 5-time chair stand test (p = 0.046) and general health (p = 0.044) among the quality of life items in the short physical performance battery. Pre- and post-analyses in the experimental group showed a significant increase in appendicular skeletal muscle mass (z = -2.88, p < 0.001), right calf circumference (z = -3.59, p < 0.001), left calf circumference (t = -4.94, p < 0.001), and energy/fatigue (t = -3.25, p = 0.003) among the quality of life items. They also showed improved performance on the 5-time chair stand test (z = -4.33, p < 0.001) and significantly reduced geriatric depression (t = 3.13, p = 0.002). The forest-based intervention for sarcopenia prevention improved physical function and psychological well-being in older adult women.

Background: Type 2 diabetes mellitus involves multifactorial metabolic dysfunction necessitating therapeutic strategies capable of modulating multiple biological pathways.Methods: This study implemented a 4-stage integrated screening platform to identify natural products with multitarget antidiabetic potential.Results: Five plant samples samples were evaluated through α-glucosidase inhibition, protein tyrosine phosphatase 1B inhibition, glucoseuptake enhancement assays in C2C12 myotubes, and network pharmacology. Amongst them, Lagerstroemia speciosa (banaba leaf) was the only material that demonstrated coherent activity across all assays. Banaba extract significantly inhibited α-glucosidase, enhanced glucose uptake in a dose-dependent manner, and exhibited measurable protein tyrosine phosphatase suppression. Network pharmacology further supported these findings and 13 overlapping targets and 19 hub genes enriched in insulin signaling pathways (PI3K-Akt, AMPK, MAPK, and FOXO) were identified. This reflected strong mechanistic relevance of banaba leaf to Type 2 diabetes mellitus.Conclusion: Collectively, these results demonstrate the utility of a systematic, multilevel screening framework which highlights banaba leaf as a promising candidate for further antidiabetic research. Nevertheless, reliance on in vitro and in silico analyses underscores the need for in vivo validation to determine physiological efficacy, bioavailability, and systemic metabolic effects.